This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Licentia, Ltd.. Active years: 2008.
Company Filing History:
Years Active: 2008
Title: Jari Leinonen: Innovator in Prostate Cancer Research
Introduction
Jari Leinonen is a notable inventor based in Helsinki, Finland. He has made significant contributions to the field of medical research, particularly in the area of prostate cancer diagnostics and treatment. His innovative work has led to the development of novel peptide ligands that specifically bind to prostate-specific antigen (PSA).
Latest Patents
Leinonen holds a patent for "Peptide ligands for prostate specific antigen." This invention relates to novel peptide ligands that enhance the enzyme activity of PSA. The patent encompasses a process for preparing these peptides, as well as their use in diagnostic and pharmaceutical compositions. The peptides can be utilized in various methods for determining the concentrations of different molecular forms of PSA and for modulating PSA enzyme activity in both in vivo and in vitro settings.
Career Highlights
Throughout his career, Jari Leinonen has worked with companies such as Licentia Ltd. and Licentia Oy. His experience in these organizations has allowed him to further his research and development efforts in the medical field. His work has been instrumental in advancing the understanding and treatment of prostate cancer.
Collaborations
Leinonen has collaborated with notable colleagues, including Erkki Koivunen and Ale Närvänen. These partnerships have contributed to the success of his research and the development of innovative solutions in the medical field.
Conclusion
Jari Leinonen's contributions to prostate cancer research through his innovative patents and collaborations highlight his importance in the field. His work continues to pave the way for advancements in diagnostics and treatment options for patients.